Synopsis
Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic Acid Methyamide-4-methylbenzenesulfonate
2. Bay 43 9006
3. Bay 43-9006
4. Bay 439006
5. Bay 545 9085
6. Bay 545-9085
7. Bay 5459085
8. Bay 673472
9. Bay-545-9085
10. Bay-673472
11. Bay5459085
12. Nexavar
13. Sorafenib
14. Sorafenib N Oxide
15. Sorafenib N-oxide
1. 475207-59-1
2. Nexavar
3. Sorafenib Tosylate [usan]
4. Sorafenib (tosylate)
5. Sorafenib Tosilate
6. Bay 54-9085
7. 475207-59-1 (tosylate)
8. 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-n-methylpicolinamide 4-methylbenzenesulfonate
9. Chebi:50928
10. 5t62q3b36j
11. Mfcd08235032
12. Bay-54-9085
13. Sorafenib Tosilate (jan)
14. Sorafenib (nexavar)
15. Sorafenib Tosylate (usan)
16. Nexavar(r)
17. Dsstox_cid_27817
18. Dsstox_rid_82581
19. Dsstox_gsid_47839
20. 1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(4-((2-(methylcarbamoyl)pyridin-4-yl)oxy)phenyl)urea Mono(4-methylbenzenesulfonate)
21. 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-n2-methylpyridine-2-carboxamide Mono (4-methylbenzenesulfonate)
22. 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methylpyridine-2-carboxamide;4-methylbenzenesulfonic Acid
23. Sorafenib Tosilate [jan]
24. Bay 43-9006 Tosylate
25. 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-n-methylpicolinamide 4-methylbenzenesulfonate.
26. 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-n-methylpyridine-2-carboxamide; 4-methylbenzene-1-sulfonic Acid
27. Cas-475207-59-1
28. Nsc-724772
29. Ncgc00167488-01
30. Unii-5t62q3b36j
31. Sr-00000000529
32. Orafenib Tosylate
33. Bay43-9006 Mono-p-tosylate
34. Bay 43-9006 Mono-p-tosylate
35. 4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)phenoxy)-n-methylpyridine-2-carboxamide 4-methylbenzenesulfonate
36. 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-n-methylpyridine-2-carboxamide 4-methylbenzenesulfonate
37. Nexavar (tn)
38. Nsc724772
39. Sorafenib - Nexavar
40. Sorafenib Tsoh Salt
41. Mls002415564
42. Sorafenib Tosylate [mi]
43. Chembl1200485
44. Dtxsid9047839
45. Sorafenib (bay-43-9006)
46. Hms2219e08
47. Hms3654i09
48. Sorafenib, P-toluenesulfonate Salt
49. Sorafenib Tosilate [mart.]
50. Sorafenib Tosilate [who-dd]
51. Sorafenib Tosylate [usp-rs]
52. Tox21_112489
53. Hy-10201a
54. S1040
55. Akos015924650
56. Akos027469919
57. Tox21_112489_1
58. Ac-6799
59. Ccg-208000
60. Cs-0164
61. Nd-0228
62. Sorafenib Tosylate [orange Book]
63. Ncgc00167488-08
64. Sorafenib Tosilate [ep Monograph]
65. 2-pyridinecarboxamide, 4-(4-((((4-chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-n-methyl-, Mono(4-methylbenzenesulfonate)
66. Bs164414
67. Smr001339079
68. Sorafenib Tosylate [usp Monograph]
69. Sy012324
70. Bcp0726000112
71. Am20090612
72. Ft-0650737
73. Ft-0698449
74. Sw202562-3
75. Ec-000.2356
76. A25518
77. D06272
78. S-8502
79. 207s591
80. Q-201729
81. Sr-00000000529-5
82. 2,5-dioxo-1,4-cyclohexanedicarboxylicaciddimethylester
83. Q27122250
84. 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-n-methylpicolinamide Tosylate
85. 2-pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-n-methyl-, 4-methylbenzenesulfonate (1:1)
86. 4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)phenoxy)-n-methylpyridine-2-carboxamide 4-methylbenzenesulphonate
87. 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-n-methylpicolinamide4-methylbenzenesulfonate
88. 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methyl-2-pyridinecarboxamide Tosylate
89. 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methylpyridine-2-carboxamide;hydron;4-methylbenzenesulfonate
90. 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)-amino]phenoxy}-n-methylpyridine-2-carboxamide Tosylate
91. 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n -methylpyridine-2-carboxamide Tosylate
92. 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n-methylpyridine-2-carboxamide Tosylate
93. 4-{4-[3-(4-chloro-3-trifluoromethyl-phenyl)-ureido]-phenoxy} -pyridine-2-carboxylic Acid Methylamide-4-methylbenzenesulfonate
94. 4-{4-[3-(4-cl-3-trifluoromethyl-phenyl)-ureido]-phenoxy}-pyridine-2-carboxylic Acid Methylamide 4-methylbenzenesulfonate
95. 4-methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-n-(5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide Monomethanesulfonate
Molecular Weight | 637.0 g/mol |
---|---|
Molecular Formula | C28H24ClF3N4O6S |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 10 |
Rotatable Bond Count | 6 |
Exact Mass | 636.1057179 g/mol |
Monoisotopic Mass | 636.1057179 g/mol |
Topological Polar Surface Area | 155 Ų |
Heavy Atom Count | 43 |
Formal Charge | 0 |
Complexity | 853 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Nexavar |
PubMed Health | Sorafenib (By mouth) |
Drug Classes | Antineoplastic Agent |
Drug Label | NEXAVAR, a kinase inhibitor, is the tosylate salt of sorafenib. Sorafenib tosylate has the chemical name 4-(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)N2-methylpyridine-2-carboxamide 4-methylbenzenesulfonate and its structural formula is... |
Active Ingredient | Sorafenib tosylate |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 200mg base |
Market Status | Prescription |
Company | Bayer Hlthcare |
2 of 2 | |
---|---|
Drug Name | Nexavar |
PubMed Health | Sorafenib (By mouth) |
Drug Classes | Antineoplastic Agent |
Drug Label | NEXAVAR, a kinase inhibitor, is the tosylate salt of sorafenib. Sorafenib tosylate has the chemical name 4-(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)N2-methylpyridine-2-carboxamide 4-methylbenzenesulfonate and its structural formula is... |
Active Ingredient | Sorafenib tosylate |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 200mg base |
Market Status | Prescription |
Company | Bayer Hlthcare |
* Hepatocellular carcinoma:
Nexavar is indicated for the treatment of hepatocellular carcinoma.
* Renal cell carcinoma:
Nexavar is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.
* Differentiated thyroid carcinoma:
Nexavar is indicated for the treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hrthle cell) thyroid carcinoma, refractory to radioactive iodine.
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
L01EX02
GDUFA
DMF Review : Complete
Rev. Date : 2018-07-27
Pay. Date : 2018-01-19
DMF Number : 32140
Submission : 2017-12-20
Status : Active
Type : II
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37229
Submission : 2022-06-30
Status : Active
Type : II
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
GDUFA
DMF Review : Complete
Rev. Date : 2016-04-01
Pay. Date : 2016-02-01
DMF Number : 30234
Submission : 2016-02-23
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2016-01-26
Pay. Date : 2015-11-19
DMF Number : 29941
Submission : 2015-11-29
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2016-12-22
Pay. Date : 2016-09-30
DMF Number : 30180
Submission : 2016-01-30
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 24578
Submission : 2011-03-10
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-09-09
Pay. Date : 2014-02-25
DMF Number : 26693
Submission : 2012-12-21
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 28556
Submission : 2014-09-23
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26460
Submission : 2012-09-18
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2015-09-18
Pay. Date : 2015-06-12
DMF Number : 29340
Submission : 2015-06-30
Status : Active
Type : II
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
Certificate Number : CEP 2022-386 - Rev 00
Status : Valid
Issue Date : 2024-11-15
Type : Chemical
Substance Number : 2931
Certificate Number : CEP 2021-324 - Rev 01
Status : Valid
Issue Date : 2024-11-25
Type : Chemical
Substance Number : 2931
Certificate Number : CEP 2021-430 - Rev 01
Status : Valid
Issue Date : 2023-09-15
Type : Chemical
Substance Number : 2931
Sorafenib Tosilate, Micronised, Polymorphic Form...
Certificate Number : CEP 2023-250 - Rev 02
Status : Valid
Issue Date : 2025-05-16
Type : Chemical
Substance Number : 2931
Registration Number : 230MF10114
Registrant's Address : 7-2-A2,Hetero Corporate,Industrial Estates Sanath Nagar,Hyderabad-500 018 Telangana I...
Initial Date of Registration : 2018-08-22
Latest Date of Registration : 2018-08-22
Date of Issue : 2022-06-17
Valid Till : 2025-02-07
Written Confirmation Number : WC-0082
Address of the Firm : Karakhadi Plot No. 842-843, At - Karakhdi, Tal. - Padra, Dist - Vadodara 391 450...
Date of Issue : 2022-09-30
Valid Till : 2025-04-14
Written Confirmation Number : WC-340n
Address of the Firm : RS No: 578, Near Effluent Channel, at & Post: Luna, Taluka: Padra, District: Vad...
Date of Issue : 2022-09-30
Valid Till : 2025-04-14
Written Confirmation Number : WC-0340
Address of the Firm : R.S No: 578, Near Effluent Channel, at & Post: Luna, Taluka: Padra, District: Va...
Date of Issue : 2022-11-08
Valid Till : 2025-08-08
Written Confirmation Number : WC-0138
Address of the Firm : Plot No. 285, 286 & 287, Bommasandra-Jigani Link Road, Industrial Area, KIADB, 4...
Date of Issue : 2022-07-16
Valid Till : 2025-08-08
Written Confirmation Number : WC-0041
Address of the Firm : Unit-I, Sy. No. 10, I.D.A, Gaddapotharam (V), Jinnaram (M), Sangareddy District,...
Date of Issue : 2022-09-02
Valid Till : 2025-05-05
Written Confirmation Number : WC-0349
Address of the Firm : Unit-II, Sy. No. 50, Kardanur (Village), Patancheru (Mandai), Sangareddy Distric...
Sorafenib Hemi Tosylate Monohydrate IH
Date of Issue : 2022-09-02
Valid Till : 2025-05-05
Written Confirmation Number : WC-0349
Address of the Firm : Unit-II, Sy. No. 50, Kardanur (Village), Patancheru (Mandai), Sangareddy Distric...
Date of Issue : 2022-07-15
Valid Till : 2025-06-22
Written Confirmation Number : WC-014n
Address of the Firm : Mekaguda Village, Nandigama Mandai, Rangareddy District, Telangana State, India,...
Date of Issue : 2022-07-15
Valid Till : 2025-06-22
Written Confirmation Number : WC-014
Address of the Firm : Mekaguda Village, Nandigama Mandai, Rangareddy District, Telangana State, India,...
Date of Issue : 2022-08-31
Valid Till : 2025-07-20
Written Confirmation Number : WC-0198N
Address of the Firm : R-282, TTC Area of MIDC, Rabale, Plant 3, 5 and 6, Thane- Belapur Road, Navi Mum...
Registrant Name : Bayer Korea Ltd.
Registration Date : 2007-12-28
Registration Number : Su2420-1-ND
Manufacturer Name : Bayer AG@Bayer AG
Manufacturer Address : Friedrich-Ebert-Str.217-333, 42117,Wuppertal,Germany_x000D_ @51368 leverkusen
Registrant Name : UNUST Co., Ltd.
Registration Date : 2012-07-13
Registration Number : No. 4838-16-ND
Manufacturer Name : Cipla Limited
Manufacturer Address : Plot No. 285, 286 & 287 KIADB, IV PHASE, Jigani - Bommasandra Link Road, Bommasandra,...
Registrant Name : M-Peak Korea Co., Ltd.
Registration Date : 2018-02-08
Registration Number : No. 473-19-ND(1)
Manufacturer Name : Hetero Labs Limited
Manufacturer Address : Unit-Ⅰ, Sy.No. 10, IDA, Gaddapotharam Village, Jinnaram Mandal, Sangareddy District...
Registrant Name : Sungwoo Chemical Co., Ltd.
Registration Date : 2017-12-04
Registration Number : 473-19-ND
Manufacturer Name : Hetero Labs Limited
Manufacturer Address : Unit-Ⅰ, Sy.No. 10, IDA, Gaddapotharam Village, Jinnaram Mandal, Sangareddy District...
Registrant Name : Jeil Pharmaceutical Co., Ltd.
Registration Date : 2014-11-24
Registration Number : 1668-15-ND
Manufacturer Name : Jeil Pharmaceutical Co., Ltd...
Manufacturer Address : 7, Cheonggang-ga-chang-ro, Baekam-myeon, Cheoin-gu, Yongin-si, Gyeonggi-do (B-dong an...
Registrant Name : Aging Life Science Co., Ltd.
Registration Date : 2021-04-06
Registration Number : 434-32-ND
Manufacturer Name : Natco Pharma Limited
Manufacturer Address : Chemical Division Mekaguda Village, Nandigama Mandal Rangareddy District Telangana, 5...
Registrant Name : Sampoong Pharmachem Co., Ltd.
Registration Date : 2016-03-07
Registration Number : No. 5643-3-ND
Manufacturer Name : Shandong Anhong Pharmaceutic...
Manufacturer Address : No. 29 Huayuan Street, Linyi County, Dezhou, Shandong, China
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
NDC Package Code : 62207-982
Start Marketing Date : 2023-08-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 59651-649
Start Marketing Date : 2024-01-17
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (50kg/50kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 73377-277
Start Marketing Date : 2024-05-16
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 68554-0073
Start Marketing Date : 2005-12-20
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 54893-0034
Start Marketing Date : 2015-02-17
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 54893-0127
Start Marketing Date : 2024-05-29
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 54893-0089
Start Marketing Date : 2019-03-29
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 63850-8051
Start Marketing Date : 2016-01-20
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 69262-0002
Start Marketing Date : 2022-11-09
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.
About the Company : MINAKEM is a cGMP custom manufacturer of small molecule API, HPAPI and steroids. All development and manufacturing activities are supported by highly skilled R&D teams, supported b...
About the Company : Minakem Montreal is developing and manufacturing small molecules APIs and advanced intermediates, including corticosteroids. Following efficient processes and methodologies, our em...
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...
Faran Shimi: Leading producer of high-quality APIs & alkaloid opiates, serving major pharmaceutical companies across the Middle East.
About the Company : Faran Shimi Pharmaceutical Company, established in 2001 and affiliated with Golrang Pharmaceutical Investment Co, manufactures high-quality Active Pharmaceutical Ingredients (APIs)...
About the Company : Established in May 2012, Shandong Loncom Pharmaceutical operates as a fully owned subsidiary of Shandong Bestcomm Pharmaceutical Co., Ltd. Situated in the Qihe Economic Development...
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
About the Company : Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediates and biological API...
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
About the Company : Granules is a fast-growing, vertically integrated pharma company based in Hyderabad, committed to operational excellence, quality, and customer service. It manufactures across the ...
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
About the Company : Founded in 1935, TAPI Technology & API Services has a long-standing tradition of advancing health through innovation and dedication. Today, we proudly build upon this legacy, drivi...
About the Company : Sumar Biotech LLP, registered in January 2018, is a startup approved by the Gujarat State Biotechnology Mission. It was founded by emerging entrepreneurs and a team of young yet ex...
About the Company : Acebright ensures and adherence to HSE practices. Our infrastructure for oncology APIs supports capacity of 35MTs plus annually, having line 1 (20MTs) & line 2 (15MTs) separately. ...
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
VDA-1275 is a potent small molecule new chemical entity (NCE) with novel mechanism of action that selectively modulates VDAC/HK2 interaction. It is being developed for the treatment of solid tumors.
Lead Product(s): VDA-1275,Cisplatin,Sorafenib
Therapeutic Area: Oncology Brand Name: VDA-1275
Study Phase: PreclinicalProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 19, 2024
Lead Product(s) : VDA-1275,Cisplatin,Sorafenib
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Vidac Presents High Efficacy Data For Next-Generation Cancer Drug Candidate In Solid Tumor
Details : VDA-1275 is a potent small molecule new chemical entity (NCE) with novel mechanism of action that selectively modulates VDAC/HK2 interaction. It is being developed for the treatment of solid tumors.
Product Name : VDA-1275
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 19, 2024
Details:
CVM-1118 (foslinanib) is a new small molecule chemical entity and a potential anti-cancer agent in numerous human cancer cell lines with strong anti-cancer activity, high safety margin, and multiple mechanisms of actions in targeting cancer-specific factors.
Lead Product(s): Foslinanib,Sorafenib
Therapeutic Area: Oncology Brand Name: CVM-1118
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: TaiRx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 27, 2022
Lead Product(s) : Foslinanib,Sorafenib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : TaiRx
Deal Size : Undisclosed
Deal Type : Partnership
Bora Pharmaceuticals Partners with TaiRx
Details : CVM-1118 (foslinanib) is a new small molecule chemical entity and a potential anti-cancer agent in numerous human cancer cell lines with strong anti-cancer activity, high safety margin, and multiple mechanisms of actions in targeting cancer-specific fact...
Product Name : CVM-1118
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 27, 2022
Details:
OUTREACH-2 study evaluating MTL-CEBPA specifically up-regulates CCAAT/enhancer-binding protein alpha (C/EBP-α) in combination with sorafenib, in comparison to sorafenib alone, in up to 150 patients.
Lead Product(s): MTL-CEBPA,Sorafenib
Therapeutic Area: Oncology Brand Name: MTL-CEBPA
Study Phase: Phase IIProduct Type: Oligonucleotide
Sponsor: Bayer AG
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 25, 2022
Details : OUTREACH-2 study evaluating MTL-CEBPA specifically up-regulates CCAAT/enhancer-binding protein alpha (C/EBP-α) in combination with sorafenib, in comparison to sorafenib alone, in up to 150 patients.
Product Name : MTL-CEBPA
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
January 25, 2022
Details:
The median sorafenib treatment duration was only nine weeks, a much shorter treatment duration than the referenced historical controls. The median treatment duration of TTFields was 10 weeks.
Lead Product(s): Sorafenib
Therapeutic Area: Oncology Brand Name: Nexavar
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 07, 2021
Details : The median sorafenib treatment duration was only nine weeks, a much shorter treatment duration than the referenced historical controls. The median treatment duration of TTFields was 10 weeks.
Product Name : Nexavar
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 07, 2021
Details:
Last patient has been enrolled in the HEPANOVA trial, a phase 2 pilot trial testing Tumor Treating Fields in combination with sorafenib in patients with advanced liver cancer.
Lead Product(s): Sorafenib
Therapeutic Area: Oncology Brand Name: Nexavar
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 07, 2020
Details : Last patient has been enrolled in the HEPANOVA trial, a phase 2 pilot trial testing Tumor Treating Fields in combination with sorafenib in patients with advanced liver cancer.
Product Name : Nexavar
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 07, 2020
Details:
The randomized, placebo-controlled Phase 2b study of YIV-906 is evaluating efficacy, safety, and quality of life in patients with hepatitis B-positive HCC.
Lead Product(s): YIV-906,Sorafenib
Therapeutic Area: Oncology Brand Name: YIV-906
Study Phase: Phase IIProduct Type: Plant Extract/Herbal
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 04, 2020
Details : The randomized, placebo-controlled Phase 2b study of YIV-906 is evaluating efficacy, safety, and quality of life in patients with hepatitis B-positive HCC.
Product Name : YIV-906
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
June 04, 2020
Details:
Observed clinical activity, including durable and complete tumour responses, suggests that MTL-CEBPA may increase the effectiveness of sorafenib standard of care.
Lead Product(s): MTL-CEBPA,Sorafenib
Therapeutic Area: Oncology Brand Name: MTL-CEBPA
Study Phase: Phase IProduct Type: Oligonucleotide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 29, 2020
MiNA Therapeutics Presents Top Line Results from Phase Ib Study of MTL‑CEBPA in Combination with...
Details : Observed clinical activity, including durable and complete tumour responses, suggests that MTL-CEBPA may increase the effectiveness of sorafenib standard of care.
Product Name : MTL-CEBPA
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
May 29, 2020
N-Methyl-4-chloro-2-pyridinecarboxamide
CAS Number : 220000-87-3
End Use API : Sorafenib
About The Company : Established in May 2012, Shandong Loncom Pharmaceutical operates as a fully owned subsidiary of Shandong Bestcomm Pharmaceutical Co., Ltd. Situated in the Qihe ...
CAS Number : 123-30-8
End Use API : Sorafenib
About The Company : Established in May 2012, Shandong Loncom Pharmaceutical operates as a fully owned subsidiary of Shandong Bestcomm Pharmaceutical Co., Ltd. Situated in the Qihe ...
4-(4-Aminophenoxy)-N-methyl-2- pyridinecarboxamide
CAS Number : 284462-37-9
End Use API : Sorafenib
About The Company : Established in May 2012, Shandong Loncom Pharmaceutical operates as a fully owned subsidiary of Shandong Bestcomm Pharmaceutical Co., Ltd. Situated in the Qihe ...
4-[4-[3-[4-Chloro-3- (trifluoromethyl)phenyl]ureid...
CAS Number : 284461-73-0
End Use API : Sorafenib
About The Company : Established in May 2012, Shandong Loncom Pharmaceutical operates as a fully owned subsidiary of Shandong Bestcomm Pharmaceutical Co., Ltd. Situated in the Qihe ...
4-(4-Aminophenoxy)-N-methylpyridine-2-carboxamide
CAS Number : 284462-37-9
End Use API : Sorafenib
About The Company : Established in May 2012, Shandong Loncom Pharmaceutical operates as a fully owned subsidiary of Shandong Bestcomm Pharmaceutical Co., Ltd. Situated in the Qihe ...
Methyl 4-chloro-2-pyridinecarboxylate hydrochlorid...
CAS Number : 176977-85-8
End Use API : Sorafenib
About The Company : Chengda Pharmaceutical Co., Ltd. was founded in 1999. It is located in the Hangzhou-Jiaxing-Huzhou plain, Jiashan Economic & Technological Development Zone (nat...
4-(4-Amino-3-fluorophenoxy)-N-methylpyridine-2-car...
CAS Number : 757251-39-1
End Use API : Sorafenib
About The Company : Glenfin Chemicals, a trusted provider of high-quality chemical solutions tailored to meet the diverse needs of industries worldwide. Based in the heart of inno...
N-Methyl-4-chloropyridine-2-carboxamide / HCl
CAS Number : 220000-87-3
End Use API : Sorafenib
About The Company : Glenfin Chemicals, a trusted provider of high-quality chemical solutions tailored to meet the diverse needs of industries worldwide. Based in the heart of inno...
4-Chloro-N-methyl-2-pyridinecarboxamide
CAS Number : 220000-87-3
End Use API : Sorafenib
About The Company : Green Stone Swiss Co ., ltd.is a high-tech enterprise of pharmaceuticals and health ingredients, and provide customized products/OEM/ODM. We signed technical co...
4-(4-Aminophenyloxy)-N-methyl-2-pyridininecarb oxa...
CAS Number : 284462-37-9
End Use API : Sorafenib
About The Company : Green Stone Swiss Co ., ltd.is a high-tech enterprise of pharmaceuticals and health ingredients, and provide customized products/OEM/ODM. We signed technical co...
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
82
PharmaCompass offers a list of Sorafenib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Sorafenib manufacturer or Sorafenib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Sorafenib manufacturer or Sorafenib supplier.
PharmaCompass also assists you with knowing the Sorafenib API Price utilized in the formulation of products. Sorafenib API Price is not always fixed or binding as the Sorafenib Price is obtained through a variety of data sources. The Sorafenib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Sorafenib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Sorafenib, including repackagers and relabelers. The FDA regulates Sorafenib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Sorafenib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Sorafenib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Sorafenib supplier is an individual or a company that provides Sorafenib active pharmaceutical ingredient (API) or Sorafenib finished formulations upon request. The Sorafenib suppliers may include Sorafenib API manufacturers, exporters, distributors and traders.
click here to find a list of Sorafenib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Sorafenib DMF (Drug Master File) is a document detailing the whole manufacturing process of Sorafenib active pharmaceutical ingredient (API) in detail. Different forms of Sorafenib DMFs exist exist since differing nations have different regulations, such as Sorafenib USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Sorafenib DMF submitted to regulatory agencies in the US is known as a USDMF. Sorafenib USDMF includes data on Sorafenib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Sorafenib USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Sorafenib suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Sorafenib Drug Master File in Japan (Sorafenib JDMF) empowers Sorafenib API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Sorafenib JDMF during the approval evaluation for pharmaceutical products. At the time of Sorafenib JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Sorafenib suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Sorafenib Drug Master File in Korea (Sorafenib KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Sorafenib. The MFDS reviews the Sorafenib KDMF as part of the drug registration process and uses the information provided in the Sorafenib KDMF to evaluate the safety and efficacy of the drug.
After submitting a Sorafenib KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Sorafenib API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Sorafenib suppliers with KDMF on PharmaCompass.
A Sorafenib CEP of the European Pharmacopoeia monograph is often referred to as a Sorafenib Certificate of Suitability (COS). The purpose of a Sorafenib CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Sorafenib EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Sorafenib to their clients by showing that a Sorafenib CEP has been issued for it. The manufacturer submits a Sorafenib CEP (COS) as part of the market authorization procedure, and it takes on the role of a Sorafenib CEP holder for the record. Additionally, the data presented in the Sorafenib CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Sorafenib DMF.
A Sorafenib CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Sorafenib CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Sorafenib suppliers with CEP (COS) on PharmaCompass.
A Sorafenib written confirmation (Sorafenib WC) is an official document issued by a regulatory agency to a Sorafenib manufacturer, verifying that the manufacturing facility of a Sorafenib active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Sorafenib APIs or Sorafenib finished pharmaceutical products to another nation, regulatory agencies frequently require a Sorafenib WC (written confirmation) as part of the regulatory process.
click here to find a list of Sorafenib suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Sorafenib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Sorafenib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Sorafenib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Sorafenib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Sorafenib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Sorafenib suppliers with NDC on PharmaCompass.
Sorafenib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Sorafenib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Sorafenib GMP manufacturer or Sorafenib GMP API supplier for your needs.
A Sorafenib CoA (Certificate of Analysis) is a formal document that attests to Sorafenib's compliance with Sorafenib specifications and serves as a tool for batch-level quality control.
Sorafenib CoA mostly includes findings from lab analyses of a specific batch. For each Sorafenib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Sorafenib may be tested according to a variety of international standards, such as European Pharmacopoeia (Sorafenib EP), Sorafenib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Sorafenib USP).